Fundraising Fox

Vigil Neuroscience

Cambridge, US · Founded 2020 · Delaware corporation · 5 known investors

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

AI & Machine LearningBiotechMedical Devices

Founders & leadership

IM
Ivana Magovcevic-LiebischExecutive
CV
Christopher VerniExecutive
MT
Mary ThistleNamed on SEC filing
ET
Evan ThackaberryNamed on SEC filing
SB
Suzanne BruhnNamed on SEC filing
GK
Gerhard KoenigNamed on SEC filing
SP
Spyros PapapetropoulosNamed on SEC filing
JZ
Jennifer ZiolkowskiNamed on SEC filing
SG
Shaan Gandhiin𝕏Named on SEC filingPrincipal at Longwood Fund

Board

BBBruce Booth
Bruce Boothin𝕏Board directorPartner at Atlas Venture
SV
Stefan VitorovicinBoard directorManaging Director at Vida Ventures
CB
Cheryl BlanchardBoard director

Investors · 5

Atlas VentureCambridge · $500K – $1M
Lightstone VenturesPortola Valley
Vida VenturesLos Angelesvia Stefan Vitorovic · board
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M
Longwood FundreportedBostonvia Shaan C. Gandhi · board

Reported raises · per SEC filings

Form D private placements

$215M disclosed across 3 rounds · 2020–2022

▶$75MraisedAug 2022 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce BoothDirector
  • Ivana Magovcevic-LiebischExecutive Officer, Director
  • Christopher VerniExecutive Officer
  • Mary ThistleDirector
  • Stefan VitorovicDirector
  • Evan ThackaberryExecutive Officer
  • Cheryl BlanchardDirector
  • Suzanne BruhnDirector
  • Gerhard KoenigDirector
  • Spyros PapapetropoulosExecutive Officer
  • Jennifer ZiolkowskiExecutive Officer
  • Shaan GandhiDirector
Offering amount
$75M
Amount sold
$75M
Sales commissions
$3.4M
Placement agents
Jefferies LLC
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$90MraisedAug 2021 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stefan VitorovicDirector
  • Shaan GandhiDirector
  • Bruce BoothDirector
  • Gerhard KoenigDirector
  • Cheryl Blanchard, Ph. D.Director
  • Jennifer ZiolkowskiExecutive Officer
  • Clay ThorpDirector
  • Ivana Magovcevic-LiebischExecutive Officer, Director
Offering amount
$90M
Amount sold
$90M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50MraisedJun 2021 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce BoothDirector
  • Shaan GandhiDirector
  • Gerhard KoenigDirector
  • Ivana Magovcevic-LiebischExecutive Officer, Director
  • Clay ThorpDirector
  • Cheryl BlanchardDirector
Offering amount
$50M
Amount sold
$50M
First sale
Sep 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Vigil Neuroscience do?
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
Who are Vigil Neuroscience's investors?
Vigil Neuroscience's investors include Atlas Venture, Lightstone Ventures, Vida Ventures, Hatteras Venture Partners, Longwood Fund.
How much funding has Vigil Neuroscience raised?
Vigil Neuroscience has disclosed $215M raised across 3 rounds.
Where is Vigil Neuroscience headquartered?
Vigil Neuroscience is headquartered in Cambridge, US.